FOXM1 and central nervous system cancer: Relevant studies have shown that MYBL2 is a key downstream factor of the Akt/FoxM1 signaling pathway in promoting human glioma progression and can be used as a new candidate gene for glioma molecular targeted therapy and a biomarker for radiotherapy [18].